# Ranibizumab and the Risk of Arterial Thromboembolic Events

> **NCT01319188** · PHASE4 · TERMINATED · sponsor: **Ural State Medical University** · enrollment: 380 (actual)

## Conditions studied

- Age-related Macular Degeneration
- Coronary Artery Disease
- Cerebrovascular Disorders

## Interventions

- **DRUG:** 0.5 mg of ranibizumab
- **PROCEDURE:** 0.5 mg of ranibizumab + photodynamic therapy
- **OTHER:** Sham injection

## Key facts

- **NCT ID:** NCT01319188
- **Lead sponsor:** Ural State Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2012-10
- **Final completion:** 2015-04
- **Target enrollment:** 380 (ACTUAL)
- **Why stopped:** The study was terminated under the political pressure of the Federal Security Service of the Russian Federation (FSB) and the Russian Society of Cardiology
- **Last updated:** 2015-05-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01319188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01319188, "Ranibizumab and the Risk of Arterial Thromboembolic Events". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01319188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*